

Medical Sciences / Pharmaceuticals | Technology Offer

Early Therapy for Cystic Fibrosis (1)

Advantages at a Glance

Early treatment with sodium channel blocker amiloride immediately following birth:

- Reduces the thick mucus in the lung, improves respiration, reduces lung infections and prolongs survival, because the accelerated salt and water absorption in the air way is effectively suppressed. Simplified registration requirements due to the orphan disease status
- Tested active substance with novel application

We are searching for:

Licensees, Funding or Cooperative Partners for the further development and clinical trials.

Application

Cystic Fibrosis (CF) is an inherited, non-curable and life-limiting autosomal recessive metabolic disease of the lung. Other organs can also be affected, e.g. pancreas, intestine and gall bladder.

Over 5% of the European population is carriers of the CF mutation; worldwide there are some 60,000 people suffering from CF. Between 300 and 400 babies with the disease are born each year in Germany alone.

Current State of Technology

At present, only the symptoms of CF are being treated, not the actual cause. Physical therapies in combination with mucus solvents help patients to remove mucus from the lung. Antibiotics are used against bacterial infections of the lung. Life expectancy under current therapeutic conditions is around 40 years.

Market Potential

The CF market is estimated to grow positively up to 2017 with a compound annual growth rate of 8.2% and a market value greater than US\$ 2,140. The market is ready for new pharmaceuticals which satisfy the unmet medical need.

Neonatal Screening for CF

The earlier the CF diagnosis occurs, the earlier treatment can commence and the better are the chances of the patient. Following this principle, the Cystic Fibrosis Center at the Heidelberg University Clinic under the leadership of Professor Marcus Mall has successfully applied a new, simple and safe biochemical CF-test (Sommerburg et al., JIMD, 2010) and is actively campaigning in support of a regular neonatal screening program for the early detection of metabolic diseases.

Innovative Therapy for CF

In parallel with the development of the screening test, Professor Mall and his team developed a novel preventive therapeutic strategy (Zhou et al., AJRCCM, 2008) for the early treatment of CF before any disease-specific symptoms can be detected. The early therapy with amiloride commencing during the first days after birth prevents the development of CF in animal trials. Further information on this is available on page 2.

Patent Situation of the new CF Therapy

A European Patent (EP211440B1) has been granted and validated in Germany, Great Britain and France. A US patent is currently pending.

TLB – Agency for the Management of Patents and Their Commercialisation

As partners of the scientific community as well as industry, we have been offering for more than a decade customized services in invention and patent management. We search and identify world-wide potential buyers or licensees for our market-focused inventions. Our objective is to create commercial value from new ideas.

Your Contact within TLB

Dr Uta Weirich

E-mail: uweirich@tlb.de

Tel.: +49-721 79004-0, Fax: +49-721 79004-79

Early Therapy for Cystic Fibrosis (2)

Results of the innovative CF Therapy

In animal trials, transgenic CF-mice (Mall et al., Nat. Med., 2004) were treated successfully with amiloride via nasal application, provided they were treated prior to CF-symptoms developing, i.e. immediately following birth (Zhou et al., AJRCCM, 2008):




Figure 1: Early treatment with amiloride immediately after birth significantly reduces mortality in CF-transgenic mice (red arrow)

In addition, the early amiloride therapy positively affects the mucus membrane and the formation of mucus (Fig. 2) as well as the goblet cell metaplasia, the chronic inflammation and the formation of lung emphysema. These results demonstrate that the preventive treatment with amiloride can be an effective therapy for CF.




Figure 2: The congestion of the lung with mucus in CF-transgenic mice can be effectively treated by an early amiloride therapy commencing in the first few days after birth up to 14 days after birth. AB-PAS staining. Scale bar = 500 μ m (wt), und 200 μ m (CF).

Preparation of Clinical Studies

Clinical trials of amiloride as a preventative early intervention therapy against CF are already in the planning phase. The start-up financing of the necessary toxicological investigations and the clinical pilot studies of amiloride, including the request for approval, is assured.

Amiloride

Amiloride is registered as a diuretic and was introduced to the market by Merck Sharp & Dohme in 1967. Amiloride acts as an epithelial sodium channel (ENaC) blocker but achieved no positive effect in inhalation studies with patients already exhibiting CF-typical symptoms.

Genetics

The CF mutation is located in the CFTR gene, which encodes a transmembrane protein acting as a chloride channel and regulator of epithelial sodium channels (ENaC). In the airways, CFTR is primarily responsible for the coordination of secretion and absorption of salt and water to maintain adequate hydration of airway surfaces and mucus, which is required for normal mucus clearance from the lungs.

TLB – Agency for the Management of Patents and Their Commercialisation

As partners of the scientific community as well as industry, we have been offering for more than a decade customized services in invention and patent management. We search and identify world-wide potential buyers or licensees for our market-focused inventions. Our objective is to create commercial value from new ideas.

Your Contact within TLB

Dr Uta Weirich

Email: uweirich@tlb.de

Tel.: +49-721 79004-0, Fax: +49-721 79004-79